ClinicalTrials.gg
CompletedNCT03682848Updated Dec 9, 2025Results posted

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

A Phase 3 interventional study of DTG + 3TC FDC in HIV Infections, sponsored by ViiV Healthcare. Completed at 8 sites in 3 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Enrollment
44th of 55
32 · median 126
Started
2019
with 7 others
Phase 3
21 of 55
2 open now
Registered
32nd of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 44th largest by enrollment, is one of 8 that started in 2019, is one of 21 in phase 3, and was the 32nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

First-line antiretroviral regimens are highly efficacious and generally well tolerated. However, as these regimens need to be taken life-long, there is growing concern about long-term toxicities associated with these regimens. Thus, there is great interest from participants and clinicians in unique regimens that might avoid such toxicities by minimizing the number of antiretrovirals without sacrificing long-term antiviral efficacy. DTG plus 3TC is a novel, well-tolerated first-line regimen for HIV-infected treatment- naive participants, limiting the risk of many common adverse reactions associated with other antiretroviral drugs. This study was designed to evaluate the efficacy and safety of DTG/3TC as an FDC in ART-naive HIV-1-infected adolescents who weighed at least 25 kilograms (kg).

The study consisted of a Screening Phase (up to 28 days prior to the first dose of drug), followed by a Treatment Phase (up to 48 weeks). Participants who successfully completed 48 weeks of therapy and continued to receive benefit from DTG/3TC FDC were eligible to enter a 96-week Extension Phase. Study participants who successfully completed both the Treatment Phase through 48 weeks and the Extension Phase through 144 weeks and continued to receive benefit from this two-drug regimen were to continue receiving DTG/3TC FDC in a Continuation Phase (after Week 144) until DTG and 3TC were both locally approved for use as part of a dual regimen and the single entities of DTG and 3TC were available to participants (e.g., through public health services), or the DTG/3TC FDC tablet, if required by local regulations, was locally approved and available (e.g., commercially or through public health services), or the participant no longer derived clinical benefit, or the participant met a protocol-defined reason for discontinuation.

All participants received the FDC of DTG/3TC (50/300 milligrams) once daily.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Viral load
  • Dolutegravir
  • Lamivudine
  • HIV-1
  • Fixed dose combination
  • DOVATO
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1-infected adolescents were 12 to \<18 years of age at the time of signing the form.
  • Weight was >25 kg at the time of signing the informed consent form.
  • Screening plasma HIV-1 RNA was between 1,000 and =500,000 c/mL.
  • Participants were antiretroviral-naive (defined as having had no prior therapy with any antiretroviral agent for the treatment of HIV following a diagnosis of HIV-1 infection). Participants who had received ART for prevention of mother-to-child transmission of HIV in the first 3 months of life were allowed. Participants who had received HIV post-exposure prophylaxis (PEP) or pre-exposure prophylaxis (PrEP) in the past were allowed as long as the last PEP/PrEP dose was = 6 months before HIV diagnosis or there was documented HIV seronegativity at least 2 months after the last prophylactic dose and prior to the date of HIV diagnosis.
  • Male and female participants were included. A female participant was eligible to participate if she was not pregnant (as confirmed by a negative serum human chorionic gonadotropin [hCG] test at Screening and a negative urine hCG test before Enrollment) and not lactating. Female participants of who were engaging in sexual activity that could have led to pregnancy had to agree to use one birth-control method from 28 days prior to the first dose of study medication until 4 weeks after the last dose of study medication (and completion of the follow-up visit). Condoms were additionally recommended, as appropriate use was the only method effective in preventing HIV-1 transmission. The investigator was responsible for ensuring that participants understood how to properly use these contraceptive methods. All participants in the study were also counseled on safer sexual practices, including the use and benefit/risk of effective barrier methods (e.g., male condoms), as well as on the risk of HIV transmission to an uninfected partner.
  • The participant's parent(s) or legal guardian, or the participant, was capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Females who were breastfeeding or who planned to become pregnant or breastfeed during the study were excluded.
  • Any evidence of active Centers for Disease Control and Prevention (CDC) Stage 3 and/or Category C or World Health Organization (WHO) Stage 4 disease-except cutaneous Kaposi's sarcoma not requiring systemic therapy-and historical or current \<200 cells/mm³ or CD4 percent \<15 percent resulted in exclusion.
  • Participants with severe hepatic impairment (Class C) as determined by the classification were excluded.
  • Participants with unstable liver disease (defined by ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, or known biliary abnormalities (except Gilbert's syndrome or asymptomatic gallstones) were excluded.
  • Evidence of virus (HBV) infection at Screening led to exclusion as follows: participants positive for HBsAg were excluded; participants negative for anti-HBs but positive for anti-HBc (negative HBsAg) and positive for HBV DNA were excluded. Participants positive for anti-HBc (negative HBsAg) and anti-HBs (past and/or current evidence) were immune to HBV and were not excluded.
  • Participants with an anticipated need for any therapy during the first 48 weeks of the study-and for any HCV therapy based on interferon or drugs with potential adverse drug-drug interactions with study treatment throughout the entire study period-were excluded.
  • Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) resulted in exclusion. Participants who were at least 24 hours post-completed treatment were eligible.
  • Participants with a history of sensitivity to any study medication or its components, or to drugs of the same class, or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, participation, were excluded.
  • Participants with ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, resected non-invasive cutaneous squamous cell carcinoma, or cervical, anal, or penile intraepithelial neoplasia were excluded. Other localized malignancies required agreement between the investigator and Study Medical Monitor for inclusion.
  • Participants who, in the investigator's judgment, posed a significant suicide risk were excluded. A recent history of suicidal behavior and/or suicidal ideation could have been considered evidence of serious suicide risk.
  • Treatment with an -1 immunotherapeutic vaccine within 90 days of Screening resulted in exclusion.
  • Treatment with radiation therapy, cytotoxic chemotherapeutic agents, or any systemic immune suppressant within 28 days of Screening resulted in exclusion.
  • Treatment with any agent with documented activity against HIV-1 in vitro within 28 days of the first study dose resulted in exclusion.
  • Receipt of any prohibited medication, and inability or unwillingness to switch to an alternative medication, resulted in exclusion.
  • Exposure to an experimental drug or vaccine within 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever was longer) prior to the first study dose resulted in exclusion.
  • Any evidence of pre-existing viral resistance based on any major resistance-associated mutation in Screening or historical results led to exclusion.
  • Any verified Grade 4 laboratory abnormality led to exclusion. A single repeat test during Screening was allowed to verify results.
  • Any acute laboratory abnormality at Screening that, in the Investigator's opinion, would have precluded participation in the study of an compound resulted in exclusion.
  • >5× the (ULN), or ALT >5× ULN with >1.5× ULN (with >35 percent direct bilirubin), resulted in exclusion.
  • \<50 mL/min/1.73 m² using the Schwartz equation resulted in exclusion.
  • Children who were wards of the state or government were excluded.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    DTG/3TC FDC

    Participants received dolutegravir/lamivudine (DTG/3TC) (50/300 mg) Fixed Dose Combination (FDC) tablets orally once daily.

    Drug: DTG + 3TC FDC

Interventions

  • DrugDTG + 3TC FDC

    Drug pages: Dolutegravir · Lamivudine

    DTG + 3TC FDC was available as a 50/300 mg tablet to be given orally once daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Less Than 50 Copies Per Milliliter (c/mL) at Week 48

    Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 48 according to the Food and Drug Administration (FDA) snapshot algorithm.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 24

    Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 24 according to the FDA snapshot algorithm.

    Time frame: Week 24

  2. Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 96

    Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 96 according to the FDA snapshot algorithm.

    Time frame: Week 96

  3. Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 144

    Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 144 according to the FDA snapshot algorithm.

    Time frame: Week 144

  4. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24

    Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 24 according to the FDA snapshot algorithm.

    Time frame: Week 24

  5. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96

    Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 96 according to the FDA snapshot algorithm.

    Time frame: Week 96

  6. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144

    Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 144 according to the FDA Snapshot algorithm.

    Time frame: Week 144

  7. Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 48

    Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 48 according to the FDA snapshot algorithm.

    Time frame: Week 48

  8. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Through 144 Weeks

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A serious adverse event is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

    Time frame: Up to 144 weeks

  9. Number of Participants With AEs Through 144 Weeks by Severity

    The Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria for grading the severity of adult and pediatric adverse events was used to assess severity. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. A higher grade indicates a greater severity.

    Time frame: Up to 144 weeks

  10. Number of Participants With Abnormal Findings for Hematology Parameters Through 144 Weeks

    Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. The DAIDS criteria for grading the severity of adult and pediatric adverse events was used to assess severity. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Up to 144 weeks

  11. Number of Participants With Abnormal Findings for Clinical Chemistry Parameters Through 144 Weeks

    Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase (ALT), carbon dioxide, alkaline phosphatase, bilirubin, direct bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Up to 144 weeks

  12. Number of Participants With Abnormal Findings for Fasting Lipids Through 144 Weeks

    Lipid assessments including cholesterol, low density lipoprotein (LDL) cholesterol, LDL Cholesterol Calculation, LDL Cholesterol Direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Up to 144 weeks

  13. Number of Participants With Abnormal Findings for Urinalysis Parameters Through 144 Weeks

    Urine samples were collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Up to 144 weeks

  14. Number of Participants Who Discontinue Treatment Due to Adverse Events Through 144 Weeks

    Time frame: Up to 144 weeks

  15. Number of Participants With Adverse Events and Serious Adverse Events Through 96 Weeks

    Time frame: Up to 96 weeks

  16. Number of Participants With Severity of Adverse Events Through 96 Weeks

    AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. The higher the grade, the more severe the symptoms.

    Time frame: Up to 96 weeks

  17. Number of Participants With Abnormal Findings for Hematology Parameters Through 96 Weeks

    Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Up to 96 weeks

  18. Number of Participants With Abnormal Findings for Clinical Chemistry Parameters Through 96 Weeks

    Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase, carbon dioxide, alkaline phosphatase, bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Up to 96 weeks

  19. Number of Participants With Abnormal Findings for Fasting Lipids Through 96 Weeks

    Lipid assessments including cholesterol, LDL cholesterol, LDL cholesterol calculation, LDL cholesterol direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Up to 96 weeks

  20. Number of Participants With Abnormal Findings for Urinalysis Parameters Through 96 Weeks

    Urine samples will be collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Up to 96 weeks

  21. Number of Participants Undergoing Viral Load Monitoring From Week 48 Through 144 Weeks

    Viral load was defined as plasma HIV-RNA \<50 copies per mL. Viral load monitoring of participants was performed from Week 48 through 144 weeks.

    Time frame: Weeks 48, 60, 72, 84, 96, 108, 120, 132, and 144

  22. Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count at Weeks 24 and 48

    Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  23. Change From Baseline in CD8+ Cell Count at Weeks 24 and 48

    Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  24. Change From Baseline in Ratio of CD4+ and CD8+ at Weeks 24 and 48

    Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  25. Number of Participants With Disease Progression From Week 24 Through Week 48

    Participants with disease progression included incidences of HIV-associated conditions, Acquired Immuno Deficiency Syndrome (AIDS) and death. HIV-associated conditions were assessed according to the 2014 HIV infection by Centers for Disease Control and Prevention (CDC) classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC.

    Time frame: Week 24 and up to Week 48

  26. Number of Participants With Any Adverse Events and Serious Adverse Events From Week 24 Through Week 48

    Time frame: Week 24 and up to Week 48

  27. Number of Participants With Severity of Adverse Events From Week 24 Through Week 48

    AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. The higher the grade, the more severe the symptoms.

    Time frame: Week 24 and up to Week 48

  28. Number of Participants With Abnormal Findings for Hematology Parameters From Week 24 Through Week 48

    Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Week 24 and up to Week 48

  29. Number of Participants With Abnormal Findings for Clinical Chemistry Parameters From Week 24 Through Week 48

    Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase, carbon dioxide, alkaline phosphatase, bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Week 24 and up to Week 48

  30. Number of Participants With Abnormal Findings for Fasting Lipids From Week 24 Through Week 48

    Lipid assessments including cholesterol, LDL cholesterol, LDL cholesterol calculation, LDL cholesterol direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Week 24 and up to Week 48

  31. Number of Participants With Abnormal Findings for Urinalysis Parameters From Week 24 Through Week 48

    Urine samples will be collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

    Time frame: Week 24 and up to Week 48

  32. Number of Participants Who Discontinued Treatment Due to Adverse Events From Week 24 Through Week 48

    Time frame: Week 24 and up to Week 48

  33. Maximum Observed Plasma Concentration (Cmax) Following Dosing With DTG and 3TC

    Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

    Time frame: Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1

  34. Time of Maximum Observed Plasma Concentration (Tmax) Following Dosing With DTG and 3TC

    Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

    Time frame: Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1

  35. Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC[0-t]) Following Dosing With DTG and 3TC

    Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

    Time frame: Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1

  36. Area Under the Curve (AUC) Over the Dosing Interval (AUC[0-tau]) Following Dosing With DTG and 3TC

    Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

    Time frame: Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1

  37. Apparent Terminal Half-life (t1/2) Following Dosing With DTG and 3TC

    Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

    Time frame: Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1

  38. Observed Pre-dose Plasma Concentration Following Dosing With DTG and 3TC

    Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

    Time frame: Pre-dose at Week 1

  39. Observed Plasma Concentration at 24 Hours Following Dosing With DTG and 3TC

    Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

    Time frame: 24 hours post-dose at Week 1

  40. Number of Participants With Observed Genotypic Resistance to DTG and 3TC

    Protocol-defined confirmed virologic withdrawal (CVW) through Week 144 was low with 1 participant meeting CVW criteria. Resistance testing failed, and therefore no genotypic data were available for this participant at the time of virologic failure.

    Time frame: Up to 144 weeks

  41. Number of Participants With Observed Phenotypic Resistance to DTG and 3TC

    Protocol-defined CVW through Week 144 was low with 1 participant meeting CVW criteria. Resistance testing failed, and therefore no phenotypic data were available for this participant at the time of virologic failure.

    Time frame: Up to 144 weeks

07

Results

Posted Aug 8, 2022

Participant flow

Participant flow — Overall Study
MilestoneDTG/3TC FDC
Started32
Completed20
Not completed12
Withdrew: Withdrawal by subject3
Withdrew: Site closed5
Withdrew: Protocol deviation1
Withdrew: Adverse event2
Withdrew: Lack of efficacy1

Outcome measures

PrimaryPercentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Less Than 50 Copies Per Milliliter (c/mL) at Week 48

Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 48 according to the Food and Drug Administration (FDA) snapshot algorithm.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Less Than 50 Copies Per Milliliter (c/mL) at Week 48
Percentage of ParticipantsDTG/3TC FDC
Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Less Than 50 Copies Per Milliliter (c/mL) at Week 4881 (64 to 93)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 24

Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 24 according to the FDA snapshot algorithm.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 24
Percentage of ParticipantsDTG/3TC FDC
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 2491 (75 to 98)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 96

Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 96 according to the FDA snapshot algorithm.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 96
Percentage of ParticipantsDTG/3TC FDC
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 9669 (50 to 84)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 144

Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 144 according to the FDA snapshot algorithm.

Time frame:
Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 144
Percentage of ParticipantsDTG/3TC FDC
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 14466 (47 to 81)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24

Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 24 according to the FDA snapshot algorithm.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
Percentage of ParticipantsDTG/3TC FDC
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 2484 (67 to 95)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96

Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 96 according to the FDA snapshot algorithm.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96
Percentage of ParticipantsDTG/3TC FDC
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 9669 (50 to 84)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144

Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 144 according to the FDA Snapshot algorithm.

Time frame:
Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144
Percentage of ParticipantsDTG/3TC FDC
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 14466 (47 to 81)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 48

Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 48 according to the FDA snapshot algorithm.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 48
Percentage of ParticipantsDTG/3TC FDC
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 4884 (67 to 95)
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Through 144 Weeks

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A serious adverse event is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Through 144 Weeks
ParticipantsDTG/3TC FDC
AEs29
SAEs5
SecondaryNumber of Participants With AEs Through 144 Weeks by Severity

The Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria for grading the severity of adult and pediatric adverse events was used to assess severity. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. A higher grade indicates a greater severity.

Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs Through 144 Weeks by Severity
ParticipantsDTG/3TC FDC
Grade 15
Grade 219
Grade 35
Grade 40
Grade 50
SecondaryNumber of Participants With Abnormal Findings for Hematology Parameters Through 144 Weeks

Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. The DAIDS criteria for grading the severity of adult and pediatric adverse events was used to assess severity. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Hematology Parameters Through 144 Weeks
ParticipantsDTG/3TC FDC
Hemoglobin — Grade 10
Hemoglobin — Grade 24
Hemoglobin — Grade 30
Hemoglobin — Grade 40
Hemoglobin — Grade 028
Leukocytes — Grade 12
Leukocytes — Grade 20
Leukocytes — Grade 30
Leukocytes — Grade 40
Leukocytes — Grade 030
Neutrophils — Grade 10
Neutrophils — Grade 21
Neutrophils — Grade 30
Neutrophils — Grade 40
Neutrophils — Grade 031
SecondaryNumber of Participants With Abnormal Findings for Clinical Chemistry Parameters Through 144 Weeks

Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase (ALT), carbon dioxide, alkaline phosphatase, bilirubin, direct bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Clinical Chemistry Parameters Through 144 Weeks
ParticipantsDTG/3TC FDC
Alanine Aminotransferase — Grade 13
Alanine Aminotransferase — Grade 21
Alanine Aminotransferase — Grade 30
Alanine Aminotransferase — Grade 40
Alanine Aminotransferase — Grade 028
Alkaline Phosphatase — Grade 11
Alkaline Phosphatase — Grade 22
Alkaline Phosphatase — Grade 30
Alkaline Phosphatase — Grade 40
Alkaline Phosphatase — Grade 029
Aspartate Aminotransferase — Grade 12
Aspartate Aminotransferase — Grade 20
Aspartate Aminotransferase — Grade 30
Aspartate Aminotransferase — Grade 40
Aspartate Aminotransferase — Grade 030
Bilirubin — Grade 11
Bilirubin — Grade 21
Bilirubin — Grade 30
Bilirubin — Grade 40
Bilirubin — Grade 030
Calcium — Grade 10
Calcium — Grade 21
Calcium — Grade 30
Calcium — Grade 41
Calcium — Grade 030
Carbon Dioxide — Grade 117
Carbon Dioxide — Grade 25
Carbon Dioxide — Grade 30
Carbon Dioxide — Grade 42
Carbon Dioxide — Grade 08
Creatine Kinase — Grade 12
Creatine Kinase — Grade 22
Creatine Kinase — Grade 32
Creatine Kinase — Grade 40
Creatine Kinase — Grade 026
Creatinine — Grade 12
Creatinine — Grade 20
Creatinine — Grade 30
Creatinine — Grade 40
Creatinine — Grade 030
Direct Bilirubin — Grade 10
Direct Bilirubin — Grade 20
Direct Bilirubin — Grade 31
Direct Bilirubin — Grade 40
Direct Bilirubin — Grade 031
GFR from Creatinine Adjusted for BSA — Grade 10
GFR from Creatinine Adjusted for BSA — Grade 214
GFR from Creatinine Adjusted for BSA — Grade 35
GFR from Creatinine Adjusted for BSA — Grade 40
GFR from Creatinine Adjusted for BSA — Grade 013
Potassium — Grade 12
Potassium — Grade 20
Potassium — Grade 30
Potassium — Grade 40
Potassium — Grade 030
Sodium — Grade 16
Sodium — Grade 21
Sodium — Grade 30
Sodium — Grade 40
Sodium — Grade 025
SecondaryNumber of Participants With Abnormal Findings for Fasting Lipids Through 144 Weeks

Lipid assessments including cholesterol, low density lipoprotein (LDL) cholesterol, LDL Cholesterol Calculation, LDL Cholesterol Direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Fasting Lipids Through 144 Weeks
ParticipantsDTG/3TC FDC
Cholesterol — Grade 17
Cholesterol — Grade 21
Cholesterol — Grade 30
Cholesterol — Grade 40
Cholesterol — Grade 024
LDL Cholesterol — Grade 12
LDL Cholesterol — Grade 20
LDL Cholesterol — Grade 30
LDL Cholesterol — Grade 40
LDL Cholesterol — Grade 030
LDL Cholesterol Calculation — Grade 12
LDL Cholesterol Calculation — Grade 20
LDL Cholesterol Calculation — Grade 30
LDL Cholesterol Calculation — Grade 40
LDL Cholesterol Calculation — Grade 030
LDL Cholesterol Direct — Grade 16
LDL Cholesterol Direct — Grade 23
LDL Cholesterol Direct — Grade 30
LDL Cholesterol Direct — Grade 40
LDL Cholesterol Direct — Grade 023
Triglycerides — Grade 15
Triglycerides — Grade 20
Triglycerides — Grade 30
Triglycerides — Grade 40
Triglycerides — Grade 027
SecondaryNumber of Participants With Abnormal Findings for Urinalysis Parameters Through 144 Weeks

Urine samples were collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Urinalysis Parameters Through 144 Weeks
ParticipantsDTG/3TC FDC
Urinary Glucose — Grade 11
Urinary Glucose — Grade 20
Urinary Glucose — Grade 30
Urinary Glucose — Grade 40
Urinary Glucose — Grade 031
Urinary Protein — Grade 15
Urinary Protein — Grade 22
Urinary Protein — Grade 30
Urinary Protein — Grade 40
Urinary Protein — Grade 025
Urine Erythrocytes — Grade 12
Urine Erythrocytes — Grade 20
Urine Erythrocytes — Grade 30
Urine Erythrocytes — Grade 40
Urine Erythrocytes — Grade 030
SecondaryNumber of Participants Who Discontinue Treatment Due to Adverse Events Through 144 Weeks
Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Treatment Due to Adverse Events Through 144 Weeks
ParticipantsDTG/3TC FDC
Number of Participants Who Discontinue Treatment Due to Adverse Events Through 144 Weeks2
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events Through 96 Weeks
Time frame:
Up to 96 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events Through 96 Weeks
ParticipantsDTG/3TC FDC
AEs29
SAEs3
SecondaryNumber of Participants With Severity of Adverse Events Through 96 Weeks

AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. The higher the grade, the more severe the symptoms.

Time frame:
Up to 96 weeks
Reported as:
Count of participants · Participants
Number of Participants With Severity of Adverse Events Through 96 Weeks
ParticipantsDTG/3TC FDC
Grade 18
Grade 219
Grade 32
Grade 40
Grade 50
SecondaryNumber of Participants With Abnormal Findings for Hematology Parameters Through 96 Weeks

Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Up to 96 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Hematology Parameters Through 96 Weeks
ParticipantsDTG/3TC FDC
Hemoglobin — Grade 10
Hemoglobin — Grade 24
Hemoglobin — Grade 30
Hemoglobin — Grade 40
Hemoglobin — Grade 028
Leukocytes — Grade 12
Leukocytes — Grade 20
Leukocytes — Grade 30
Leukocytes — Grade 40
Leukocytes — Grade 030
Neutrophils — Grade 10
Neutrophils — Grade 21
Neutrophils — Grade 30
Neutrophils — Grade 40
Neutrophils — Grade 031
SecondaryNumber of Participants With Abnormal Findings for Clinical Chemistry Parameters Through 96 Weeks

Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase, carbon dioxide, alkaline phosphatase, bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Up to 96 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Clinical Chemistry Parameters Through 96 Weeks
ParticipantsDTG/3TC FDC
Alanine Aminotransferase — Grade 12
Alanine Aminotransferase — Grade 21
Alanine Aminotransferase — Grade 30
Alanine Aminotransferase — Grade 40
Alanine Aminotransferase — Grade 029
Alkaline Phosphatase — Grade 11
Alkaline Phosphatase — Grade 22
Alkaline Phosphatase — Grade 30
Alkaline Phosphatase — Grade 40
Alkaline Phosphatase — Grade 029
Aspartate Aminotransferase — Grade 12
Aspartate Aminotransferase — Grade 20
Aspartate Aminotransferase — Grade 30
Aspartate Aminotransferase — Grade 40
Aspartate Aminotransferase — Grade 030
Bilirubin — Grade 12
Bilirubin — Grade 20
Bilirubin — Grade 30
Bilirubin — Grade 40
Bilirubin — Grade 030
Calcium — Grade 10
Calcium — Grade 21
Calcium — Grade 30
Calcium — Grade 41
Calcium — Grade 030
Carbon Dioxide — Grade 114
Carbon Dioxide — Grade 25
Carbon Dioxide — Grade 30
Carbon Dioxide — Grade 42
Carbon Dioxide — Grade 011
Creatine Kinase — Grade 12
Creatine Kinase — Grade 21
Creatine Kinase — Grade 32
Creatine Kinase — Grade 40
Creatine Kinase — Grade 027
Creatinine — Grade 12
Creatinine — Grade 20
Creatinine — Grade 30
Creatinine — Grade 40
Creatinine — Grade 030
GFR from Creatinine Adjusted for BSA — Grade 10
GFR from Creatinine Adjusted for BSA — Grade 213
GFR from Creatinine Adjusted for BSA — Grade 35
GFR from Creatinine Adjusted for BSA — Grade 40
GFR from Creatinine Adjusted for BSA — Grade 014
Potassium — Grade 12
Potassium — Grade 20
Potassium — Grade 30
Potassium — Grade 40
Potassium — Grade 030
Sodium — Grade 15
Sodium — Grade 21
Sodium — Grade 30
Sodium — Grade 40
Sodium — Grade 026
SecondaryNumber of Participants With Abnormal Findings for Fasting Lipids Through 96 Weeks

Lipid assessments including cholesterol, LDL cholesterol, LDL cholesterol calculation, LDL cholesterol direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Up to 96 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Fasting Lipids Through 96 Weeks
ParticipantsDTG/3TC FDC
Cholesterol — Grade 17
Cholesterol — Grade 21
Cholesterol — Grade 30
Cholesterol — Grade 40
Cholesterol — Grade 024
LDL Cholesterol — Grade 12
LDL Cholesterol — Grade 20
LDL Cholesterol — Grade 30
LDL Cholesterol — Grade 40
LDL Cholesterol — Grade 030
LDL Cholesterol Calculation — Grade 11
LDL Cholesterol Calculation — Grade 20
LDL Cholesterol Calculation — Grade 30
LDL Cholesterol Calculation — Grade 40
LDL Cholesterol Calculation — Grade 031
LDL Cholesterol Direct — Grade 16
LDL Cholesterol Direct — Grade 22
LDL Cholesterol Direct — Grade 30
LDL Cholesterol Direct — Grade 40
LDL Cholesterol Direct — Grade 024
Triglycerides — Grade 14
Triglycerides — Grade 20
Triglycerides — Grade 30
Triglycerides — Grade 40
Triglycerides — Grade 028
SecondaryNumber of Participants With Abnormal Findings for Urinalysis Parameters Through 96 Weeks

Urine samples will be collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Up to 96 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Urinalysis Parameters Through 96 Weeks
ParticipantsDTG/3TC FDC
Urinary Glucose — Grade 11
Urinary Glucose — Grade 20
Urinary Glucose — Grade 30
Urinary Glucose — Grade 40
Urinary Glucose — Grade 031
Urinary Protein — Grade 13
Urinary Protein — Grade 22
Urinary Protein — Grade 30
Urinary Protein — Grade 40
Urinary Protein — Grade 027
Urine Erythrocytes — Grade 12
Urine Erythrocytes — Grade 20
Urine Erythrocytes — Grade 30
Urine Erythrocytes — Grade 40
Urine Erythrocytes — Grade 030
SecondaryNumber of Participants Undergoing Viral Load Monitoring From Week 48 Through 144 Weeks

Viral load was defined as plasma HIV-RNA \<50 copies per mL. Viral load monitoring of participants was performed from Week 48 through 144 weeks.

Time frame:
Weeks 48, 60, 72, 84, 96, 108, 120, 132, and 144
Reported as:
Count of participants · Participants
Number of Participants Undergoing Viral Load Monitoring From Week 48 Through 144 Weeks
ParticipantsDTG/3TC FDC
Week 4828
Week 6027
Week 7223
Week 8423
Week 9623
Week 10821
Week 12021
Week 13221
Week 14421
SecondaryChange From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count at Weeks 24 and 48

Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Median · 10^6 cells per liter
Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count at Weeks 24 and 48
10^6 cells per literDTG/3TC FDC
Baseline (Day 1)371.500 (270.00 to 507.50)
Week 24167.000 (103.00 to 319.00)
Week 48223.500 (85.50 to 380.50)
SecondaryChange From Baseline in CD8+ Cell Count at Weeks 24 and 48

Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Median · 10^6 cells per liter
Change From Baseline in CD8+ Cell Count at Weeks 24 and 48
10^6 cells per literDTG/3TC FDC
Baseline (Day 1)828.000 (679.50 to 1031.50)
Week 24-15.000 (-117.00 to 301.00)
Week 48-78.500 (-243.00 to 176.00)
SecondaryChange From Baseline in Ratio of CD4+ and CD8+ at Weeks 24 and 48

Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Median · Ratio
Change From Baseline in Ratio of CD4+ and CD8+ at Weeks 24 and 48
RatioDTG/3TC FDC
Baseline (Day 1)0.395 (0.33 to 0.64)
Week 240.215 (0.14 to 0.30)
Week 480.345 (0.24 to 0.49)
SecondaryNumber of Participants With Disease Progression From Week 24 Through Week 48

Participants with disease progression included incidences of HIV-associated conditions, Acquired Immuno Deficiency Syndrome (AIDS) and death. HIV-associated conditions were assessed according to the 2014 HIV infection by Centers for Disease Control and Prevention (CDC) classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC.

Time frame:
Week 24 and up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Disease Progression From Week 24 Through Week 48
ParticipantsDTG/3TC FDC
Week 240
Week 481
SecondaryNumber of Participants With Any Adverse Events and Serious Adverse Events From Week 24 Through Week 48
Time frame:
Week 24 and up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events and Serious Adverse Events From Week 24 Through Week 48
ParticipantsDTG/3TC FDC
AEs (Week 24)23
AEs (Week 48)28
SAEs (Week 24)1
SAEs (Week 48)2
SecondaryNumber of Participants With Severity of Adverse Events From Week 24 Through Week 48

AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. The higher the grade, the more severe the symptoms.

Time frame:
Week 24 and up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Severity of Adverse Events From Week 24 Through Week 48
ParticipantsDTG/3TC FDC
Grade 1 (Week 24)9
Grade 2 (Week 24)13
Grade 3 (Week 24)1
Grade 4 (Week 24)0
Grade 5 (Week 24)0
Grade 1 (Week 48)11
Grade 2 (Week 48)16
Grade 3 (Week 48)1
Grade 4 (Week 48)0
Grade 5 (Week 48)0
SecondaryNumber of Participants With Abnormal Findings for Hematology Parameters From Week 24 Through Week 48

Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Week 24 and up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Hematology Parameters From Week 24 Through Week 48
ParticipantsDTG/3TC FDC
Hemoglobin - Grade 1 (Week 24)0
Hemoglobin - Grade 2 (Week 24)2
Hemoglobin - Grade 3 (Week 24)0
Hemoglobin - Grade 4 (Week 24)0
Leukocytes - Grade 1 (Week 24)1
Leukocytes - Grade 2 (Week 24)0
Leukocytes - Grade 3 (Week 24)0
Leukocytes - Grade 4 (Week 24)0
Neutrophils - Grade 1 (Week 24)0
Neutrophils - Grade 2 (Week 24)1
Neutrophils - Grade 3 (Week 24)0
Neutrophils - Grade 4 (Week 24)0
Hemoglobin - Grade 1 (Week 48)0
Hemoglobin - Grade 2 (Week 48)2
Hemoglobin - Grade 3 (Week 48)0
Hemoglobin - Grade 4 (Week 48)0
Leukocytes - Grade 1 (Week 48)2
Leukocytes - Grade 2 (Week 48)0
Leukocytes - Grade 3 (Week 48)0
Leukocytes - Grade 4 (Week 48)0
Neutrophils - Grade 1 (Week 48)0
Neutrophils - Grade 2 (Week 48)1
Neutrophils - Grade 3 (Week 48)0
Neutrophils - Grade 4 (Week 48)0
SecondaryNumber of Participants With Abnormal Findings for Clinical Chemistry Parameters From Week 24 Through Week 48

Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase, carbon dioxide, alkaline phosphatase, bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Week 24 and up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Clinical Chemistry Parameters From Week 24 Through Week 48
ParticipantsDTG/3TC FDC
Alanine Aminotransferase - Grade 1 (Week 24)1
Alanine Aminotransferase - Grade 2 (Week 24)0
Alanine Aminotransferase - Grade 3 (Week 24)0
Alanine Aminotransferase - Grade 4 (Week 24)0
Alkaline Phosphatase - Grade 1 (Week 24)1
Alkaline Phosphatase - Grade 2 (Week 24)2
Alkaline Phosphatase - Grade 3 (Week 24)0
Alkaline Phosphatase - Grade 4 (Week 24)0
Aspartate Aminotransferase - Grade 1 (Week 24)1
Aspartate Aminotransferase - Grade 2 (Week 24)0
Aspartate Aminotransferase - Grade 3 (Week 24)0
Aspartate Aminotransferase - Grade 4 (Week 24)0
Bilirubin - Grade 1 (Week 24)1
Bilirubin - Grade 2 (Week 24)0
Bilirubin - Grade 3 (Week 24)0
Bilirubin - Grade 4 (Week 24)0
Calcium - Grade 1 (Week 24)0
Calcium - Grade 2 (Week 24)1
Calcium - Grade 3 (Week 24)0
Calcium - Grade 4 (Week 24)1
Carbon Dioxide - Grade 1 (Week 24)11
Carbon Dioxide - Grade 2 (Week 24)4
Carbon Dioxide - Grade 3 (Week 24)0
Carbon Dioxide - Grade 4 (Week 24)2
Creatine Kinase - Grade 1 (Week 24)1
Creatine Kinase - Grade 2 (Week 24)0
Creatine Kinase - Grade 3 (Week 24)0
Creatine Kinase - Grade 4 (Week 24)0
Creatinine - Grade 1 (Week 24)1
Creatinine - Grade 2 (Week 24)0
Creatinine - Grade 3 (Week 24)0
Creatinine - Grade 4 (Week 24)0
GFR from Creatinine Adjusted for BSA - Grade 1 (Week 24)0
GFR from Creatinine Adjusted for BSA - Grade 2 (Week 24)12
GFR from Creatinine Adjusted for BSA - Grade 3 (Week 24)3
GFR from Creatinine Adjusted for BSA - Grade 4 (Week 24)0
Potassium - Grade 1 (Week 24)1
Potassium - Grade 2 (Week 24)0
Potassium - Grade 3 (Week 24)0
Potassium - Grade 4 (Week 24)0
Sodium - Grade 1 (Week 24)5
Sodium - Grade 2 (Week 24)1
Sodium - Grade 3 (Week 24)0
Sodium - Grade 4 (Week 24)0
Alanine Aminotransferase - Grade 1 (Week 48)1
Alanine Aminotransferase - Grade 2 (Week 48)0
Alanine Aminotransferase - Grade 3 (Week 48)0
Alanine Aminotransferase - Grade 4 (Week 48)0
Alkaline Phosphatase - Grade 1 (Week 48)1
Alkaline Phosphatase - Grade 2 (Week 48)2
Alkaline Phosphatase - Grade 3 (Week 48)0
Alkaline Phosphatase - Grade 4 (Week 48)0
Aspartate Aminotransferase - Grade 1 (Week 48)1
Aspartate Aminotransferase - Grade 2 (Week 48)0
Aspartate Aminotransferase - Grade 3 (Week 48)0
Aspartate Aminotransferase - Grade 4 (Week 48)0
Bilirubin - Grade 1 (Week 48)1
Bilirubin - Grade 2 (Week 48)0
Bilirubin - Grade 3 (Week 48)0
Bilirubin - Grade 4 (Week 48)0
Calcium - Grade 1 (Week 48)0
Calcium - Grade 2 (Week 48)1
Calcium - Grade 3 (Week 48)0
Calcium - Grade 4 (Week 48)1
Carbon Dioxide - Grade 1 (Week 48)12
Carbon Dioxide - Grade 2 (Week 48)5
Carbon Dioxide - Grade 3 (Week 48)0
Carbon Dioxide - Grade 4 (Week 48)2
Creatine Kinase - Grade 1 (Week 48)1
Creatine Kinase - Grade 2 (Week 48)0
Creatine Kinase - Grade 3 (Week 48)0
Creatine Kinase - Grade 4 (Week 48)0
Creatinine - Grade 1 (Week 48)2
Creatinine - Grade 2 (Week 48)0
Creatinine - Grade 3 (Week 48)0
Creatinine - Grade 4 (Week 48)0
GFR from Creatinine Adjusted for BSA - Grade 1 (Week 48)0
GFR from Creatinine Adjusted for BSA - Grade 2 (Week 48)13
GFR from Creatinine Adjusted for BSA - Grade 3 (Week 48)6
GFR from Creatinine Adjusted for BSA - Grade 4 (Week 48)0
Potassium - Grade 1 (Week 48)1
Potassium - Grade 2 (Week 48)0
Potassium - Grade 3 (Week 48)0
Potassium - Grade 4 (Week 48)0
Sodium - Grade 1 (Week 48)5
Sodium - Grade 2 (Week 48)1
Sodium - Grade 3 (Week 48)0
Sodium - Grade 4 (Week 48)0
SecondaryNumber of Participants With Abnormal Findings for Fasting Lipids From Week 24 Through Week 48

Lipid assessments including cholesterol, LDL cholesterol, LDL cholesterol calculation, LDL cholesterol direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Week 24 and up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Fasting Lipids From Week 24 Through Week 48
ParticipantsDTG/3TC FDC
Cholesterol - Grade 1 (Week 24)2
Cholesterol - Grade 2 (Week 24)0
Cholesterol - Grade 3 (Week 24)0
Cholesterol - Grade 4 (Week 24)0
LDL cholesterol - Grade 1 (Week 24)1
LDL cholesterol - Grade 2 (Week 24)0
LDL cholesterol - Grade 3 (Week 24)0
LDL cholesterol - Grade 4 (Week 24)0
Triglycerides - Grade 1 (Week 24)1
Triglycerides - Grade 2 (Week 24)0
Triglycerides - Grade 3 (Week 24)0
Triglycerides - Grade 4 (Week 24)0
Cholesterol - Grade 1 (Week 48)5
Cholesterol - Grade 2 (Week 48)1
Cholesterol - Grade 3 (Week 48)0
Cholesterol - Grade 4 (Week 48)0
LDL cholesterol - Grade 1 (Week 48)1
LDL cholesterol - Grade 2 (Week 48)0
LDL cholesterol - Grade 3 (Week 48)0
LDL cholesterol - Grade 4 (Week 48)0
Triglycerides - Grade 1 (Week 48)1
Triglycerides - Grade 2 (Week 48)0
Triglycerides - Grade 3 (Week 48)0
Triglycerides - Grade 4 (Week 48)0
SecondaryNumber of Participants With Abnormal Findings for Urinalysis Parameters From Week 24 Through Week 48

Urine samples will be collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.

Time frame:
Week 24 and up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings for Urinalysis Parameters From Week 24 Through Week 48
ParticipantsDTG/3TC FDC
Urinary Glucose - Grade 1 (Week 24)0
Urinary Glucose - Grade 2 (Week 24)0
Urinary Glucose - Grade 3 (Week 24)0
Urinary Glucose - Grade 4 (Week 24)0
Urinary Protein - Grade 1 (Week 24)0
Urinary Protein - Grade 2 (Week 24)0
Urinary Protein - Grade 3 (Week 24)0
Urinary Protein - Grade 4 (Week 24)0
Urinary Glucose - Grade 1 (Week 48)1
Urinary Glucose - Grade 2 (Week 48)0
Urinary Glucose - Grade 3 (Week 48)0
Urinary Glucose - Grade 4 (Week 48)0
Urinary Protein - Grade 1 (Week 48)1
Urinary Protein - Grade 2 (Week 48)1
Urinary Protein - Grade 3 (Week 48)0
Urinary Protein - Grade 4 (Week 48)0
SecondaryNumber of Participants Who Discontinued Treatment Due to Adverse Events From Week 24 Through Week 48
Time frame:
Week 24 and up to Week 48
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Treatment Due to Adverse Events From Week 24 Through Week 48
ParticipantsDTG/3TC FDC
Week 241
Week 481
SecondaryMaximum Observed Plasma Concentration (Cmax) Following Dosing With DTG and 3TC

Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

Time frame:
Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) Following Dosing With DTG and 3TC
Nanogram per milliliter (ng/mL)DTG/3TC FDC
Maximum observed plasma concentration - DTG5354.870 ± 25.02
Maximum observed plasma concentration - 3TC2778.555 ± 27.80
SecondaryTime of Maximum Observed Plasma Concentration (Tmax) Following Dosing With DTG and 3TC

Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

Time frame:
Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1
Reported as:
Median · Hours
Time of Maximum Observed Plasma Concentration (Tmax) Following Dosing With DTG and 3TC
HoursDTG/3TC FDC
Time of maximum observed plasma concentration - DTG2.000 (1.00 to 3.00)
Time of maximum observed plasma concentration - 3TC1.000 (1.00 to 3.00)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC[0-t]) Following Dosing With DTG and 3TC

Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

Time frame:
Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1
Reported as:
Geometric mean · hours*nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC[0-t]) Following Dosing With DTG and 3TC
hours*nanogram per milliliter (h*ng/mL)DTG/3TC FDC
AUC[0-t] - DTG74001.76 ± 23.2
AUC[0-t] - 3TC12277.62 ± 17.7
SecondaryArea Under the Curve (AUC) Over the Dosing Interval (AUC[0-tau]) Following Dosing With DTG and 3TC

Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

Time frame:
Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1
Reported as:
Geometric mean · hours*nanogram per milliliter (h*ng/mL)
Area Under the Curve (AUC) Over the Dosing Interval (AUC[0-tau]) Following Dosing With DTG and 3TC
hours*nanogram per milliliter (h*ng/mL)DTG/3TC FDC
AUC[0-tau] - DTG74001.76 ± 23.2
AUC[0-tau] - 3TC12277.62 ± 17.7
SecondaryApparent Terminal Half-life (t1/2) Following Dosing With DTG and 3TC

Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

Time frame:
Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1
Reported as:
Geometric mean · Hours
Apparent Terminal Half-life (t1/2) Following Dosing With DTG and 3TC
HoursDTG/3TC FDC
Apparent terminal half-life - DTG12.910 ± 15.35
Apparent terminal half-life - 3TC4.823 ± 13.26
SecondaryObserved Pre-dose Plasma Concentration Following Dosing With DTG and 3TC

Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

Time frame:
Pre-dose at Week 1
Reported as:
Geometric mean · ng/mL
Observed Pre-dose Plasma Concentration Following Dosing With DTG and 3TC
ng/mLDTG/3TC FDC
DTG1636.791 ± 39.26
3TC51.073 ± 60.88
SecondaryObserved Plasma Concentration at 24 Hours Following Dosing With DTG and 3TC

Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.

Time frame:
24 hours post-dose at Week 1
Reported as:
Geometric mean · ng/mL
Observed Plasma Concentration at 24 Hours Following Dosing With DTG and 3TC
ng/mLDTG/3TC FDC
DTG1635.606 ± 25.36
3TC53.453 ± 33.42
SecondaryNumber of Participants With Observed Genotypic Resistance to DTG and 3TC

Protocol-defined confirmed virologic withdrawal (CVW) through Week 144 was low with 1 participant meeting CVW criteria. Resistance testing failed, and therefore no genotypic data were available for this participant at the time of virologic failure.

Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants With Observed Genotypic Resistance to DTG and 3TC
ParticipantsDTG/3TC FDC
Number of Participants With Observed Genotypic Resistance to DTG and 3TC0
SecondaryNumber of Participants With Observed Phenotypic Resistance to DTG and 3TC

Protocol-defined CVW through Week 144 was low with 1 participant meeting CVW criteria. Resistance testing failed, and therefore no phenotypic data were available for this participant at the time of virologic failure.

Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants With Observed Phenotypic Resistance to DTG and 3TC
ParticipantsDTG/3TC FDC
Number of Participants With Observed Phenotypic Resistance to DTG and 3TC0

Adverse events

Collected over All-Cause mortality, Non-SAEs and SAEs were collected from Day 1 up to Week 144. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DTG/3TC FDC0/32 (0%)5/32 (15.6%)29/32 (90.6%)
Most frequent serious events
Most frequent serious events
EventDTG/3TC FDC
Anal abscessInfections and infestations1/32
Vulvovaginal wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/32
OrchitisInfections and infestations1/32
Ulcerative keratitisEye disorders1/32
Postoperative wound complicationInjury, poisoning and procedural complications1/32
Major depressionPsychiatric disorders1/32
Most frequent other events
Showing 10 of 32
Most frequent other events
EventDTG/3TC FDC
COVID-19Infections and infestations10/32
NasopharyngitisInfections and infestations8/32
Upper respiratory tract infectionInfections and infestations6/32
PharyngitisInfections and infestations5/32
HeadacheNervous system disorders4/32
CoughRespiratory, thoracic and mediastinal disorders4/32
FolliculitisInfections and infestations3/32
TonsillitisInfections and infestations3/32
Secondary syphilisInfections and infestations3/32
Influenza like illnessGeneral disorders3/32

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DTG/3TC FDC
Mean16.0 ± 1.27
Sex: Female, Male
Sex: Female, Male(Participants)DTG/3TC FDC
Female11
Male21
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DTG/3TC FDC
African American/African Heritage13
Asian - South East Asian Heritage19
08

Study locations

8 sites
  • GSK Investigational Site
    Kericho, 20200, Kenya
  • GSK Investigational Site
    Kisumu, 40100, Kenya
  • GSK Investigational Site
    Cape Town, 7500, South Africa
  • GSK Investigational Site
    Durban, 4001, South Africa
  • GSK Investigational Site
    Johannesburg, 1862, South Africa
  • GSK Investigational Site
    Bangkok, 10330, Thailand
  • GSK Investigational Site
    Bangkok, 10700, Thailand
  • GSK Investigational Site
    Chiang Mai, 50200, Thailand
09

References and documents

Publications

  • Puthanakit T, Aurpibul L, Lopez M, Wang M, Ciuffa M, Bontempo G, Cheung SYA, Deprez I, Buchanan AM, Vavro C, McKenna M, Min S, Tan LK. Efficacy and Safety of the Two-Drug Regimen Dolutegravir-Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b Trial. J Acquir Immune Defic Syndr. 2025 Jun 1;99(2):202-210. doi: 10.1097/QAI.0000000000003655. PubMed 39988749 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.viiv-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Dec 2021, 30 months.

Results were first posted in Aug 2022, 8 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 30 months is above that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2018
First posted
Sep 25, 2018
StartActual
May 6, 2019
Primary completionActual
Dec 1, 2021
CompletionActual
May 22, 2025
Results first posted
Aug 8, 2022
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03682848
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Sep 25, 2018
Start date
May 6, 2019
Primary completion
Dec 1, 2021
Completion
May 22, 2025
Results posted
Aug 8, 2022
Last update
Dec 9, 2025

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dolutegravir · Lamivudine

Start the discussion